Neurocrine biosciences presents demographic and clinical characteristics data of pediatric patients with scn8a-related epilepsies at aes 2022

San diego , dec. 2, 2022 /prnewswire/ -- neurocrine biosciences, inc.   (nasdaq: nbix), a leading neuroscience-focused biopharmaceutical company, today reported demographic and clinical characteristics data from genetic screening-based studies of children with scn8a-related epilepsies. data was collected from more than 17,000 patients through invitae corporation's behind the seizure® program, of which neurocrine biosciences is a sponsor.
NBIX Ratings Summary
NBIX Quant Ranking